Department of Gastroenterology and Hepatology, University Hospital Southampton NHS Foundation Trust, United Kingdom.
National Drug Research Institute, Faculty of Health Sciences, Curtin University, Australia.
J Hepatol. 2019 Feb;70(2):223-236. doi: 10.1016/j.jhep.2018.10.036.
Herein, we describe the evolving landscape of alcohol-related liver disease (ALD) including the current global burden of disease and cost to working-aged people in terms of death and disability, in addition to the larger spectrum of alcohol-related heath complications and its wider impact on society. We further review the most effective and cost-effective public health policies at both a population and individual level. Currently, abstinence is the only effective treatment for ALD, and yet because the majority of ALD remains undetected in the community abstinence is initiated too late to prevent premature death in the majority of cases. We therefore hope that this review will help inform clinicians of the "public health treatment options" for ALD to encourage engagement with policy makers and promote community-based hepatology as a speciality, expanding our patient cohort to allow early detection, and thereby a reduction in the enormous morbidity and mortality associated with this disease.
在此，我们描述了酒精性肝病（ALD）的演变情况，包括目前全球疾病负担以及酒精相关疾病对工作年龄段人群的死亡和残疾造成的经济损失，除此之外，还包括更广泛的酒精相关健康并发症及其对社会的更广泛影响。我们进一步回顾了在人群和个体层面上最有效和最具成本效益的公共卫生政策。目前，戒酒是 ALD 的唯一有效治疗方法，但由于大多数 ALD 在社区中仍未被发现，因此戒酒的时机太晚，无法预防大多数情况下的过早死亡。因此，我们希望本综述能帮助临床医生了解 ALD 的“公共卫生治疗选择”，以鼓励他们与政策制定者合作，并促进以社区为基础的肝脏病学作为一个专业，扩大我们的患者群体，以便早期发现疾病，从而降低与该疾病相关的巨大发病率和死亡率。
